EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

The relevance of circRNAs in serum of patients undergoing prostate biopsy

Lara Samirae, Philipp Krausewitz iD, Abdullah Alajati, Glen Kristiansen, Manuel Ritter, Jörg Ellinger iD

International Journal of Urology · 2024

DOI: 10.1111/iju.15414 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Urology, 2024. Verfasst von Lara Samirae und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, RNA, Circular, Prostate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First discovered in the 1970s, circular RNAs (circRNAs) were considered as unimportant RNA splicing products. circRNAs are described as a stable type of endogenous non-coding RNA, which is synthesized by back-splicing of the precursor mRNA (pre-mRNA). circRNAs consist of a loop structure with covalent bonds of head and tail. Lacking a 3′ end, circRNAs are more resistant to digestion by exonucleases compared with linear RNA. circRNAs are associated with various diseases like neurodegenerative, metabolic, and cardiovascular disorders as well as cancer, and it is assumed that circRNAs could be used as biomarkers. The knowledge about circRNAs in prostate cancer (PCA) is limited. Earlier studies investigated the expression of circRNAs in PCA tissue, indicating the upregulation of several circRNAs.1-7 in circHIPK3, circFOXO3, circZMIZ1, circSLC19A1, and circSMARCA5 were overexpressed in PCA and could therefore be of potential interest as novel biomarker. We prospectively enrolled 96 patients scheduled for prostate biopsy between February 2019 and May 2021; see Figure 1 for clinicopathological parameters of the study cohort. All patients underwent prostate biopsy for suspicion of PCA at the Department of Urology at the University Hospital Bonn. All patients provided written informed consent prior to inclusion in the study. The study was approved by the ethics committee of the University of Bonn (vote 347/19). Serum samples were treated with RNaseR to remove linear RNA prior to RNA isolation. Thereafter, serum RNA was reverse transcribed and pre-amplificated. Quantitative real-time PCR was used to determine circRNA expression; the use of divergent primers allowed specific amplification of circRNAs. Relative circRNA expression levels in cell-free serum RNA were calculated using circN4BP2L2 as a reference gene. The detailed experimental protocol including a detailed summary of the study cohort is available upon request from the authors. The recovery of serum RNA was determined using a spike-in of cel-miR-39 at the beginning of the RNA isolation procedure and quantification of cel-miR-39 using qPCR. RNA isolation failed in one patient; thus, the cohort consisted of 68 patients with PCA and 27 patients without malignancy (CTRL); see Figure 1a. The mean percentage of RNA recovery was 6.1% (range: 0.2%–22.7%). The cell-free circulating serum levels of circRNAs (circHIPK3 [p = 0.720], circFOXO3 [p = 0.263], circZMIZ1 [p = 0.166], circSLC19A1 [p = 0.735], and circSMARCA5 [p = 0.954]) were not significantly different in patients with the diagnosis of PCA or without finding of cancer in the prostate biopsy. The levels of circulating circRNAs were not correlated with the presence of significant prostate cancer. The levels of serum circZMIZ1 were significantly increased (p = 0.010) in patients with metastatic PCA (n = 8) compared with patients with localized PCA (n = 60); see Figure 1c. Furthermore, circZMIZ1 (p = 0.045) and circSLC19A1 (p = 0.035) expression in the serum of PCA patients were related to PSA levels; see Figure 1d,e. The study cohort was too small to further analyze, whether circRNA levels were useful in patients with PSA levels in the "gray zone." Knockdown of circZMIZ1 inhibited cell proliferation and induced growth arrest. The expression of circZMIZ1 was dependent on the stimulation of testosterone and increased the expression of the androgen receptor and the androgen receptor splice variant 7 (AR-V7) in vitro.2 Thus, circZMIZ1 might serve as a prognostic biomarker and probably a treatment target for the treatment of metastatic PC. In contrast, we did not observe a correlation of serum circRNA expression with DRE, prostate volume, ISUP grade, or D'Amico classification (all p > 0.05). Our findings are contrary to former studies showing an increase of circFOXO3,1 circZMIZ1,2 circSLC19A1,3-5 and circSMARCA56, 7 in blood of patients with PCA. Several important differences may explain this outcome: Earlier studies suffered from smaller sample sizes (i.e., 14–60 patients). Additionally, inadequate reference genes (mRNA) were used, and PCA patients were compared with healthy subjects. This could lead to an overestimation of the diagnostic power of circRNAs. Notably, the increase in circRNAs in tissue or cell lines3, 5 does not necessarily contribute to a relevant increase of the circRNAs in patients' circulation. The collection of serum samples was performed within the framework of the Biobank of the CIO ABCD. Open Access funding enabled and organized by Projekt DEAL. Lara Samirae: Investigation; Methodology; Formal analysis; Data curation; Visualization; Writing—original draft. Philipp Krausewitz: Writing—review & editing; Conceptualization; Supervision. Abdullah Alajati: Writing—review & editing; Methodology; Supervision; Resources. Glen Kristiansen: Supervision; Resources. Manuel Ritter: Conceptualization; Writing—review & editing; Project administration; Resources; Supervision. Jörg Ellinger: Conceptualization; Methodology; Project administration; Writing—original draft; Investigation. The authors declare no conflict of interest. The protocol for this research project has been approved by the Ethics Committee of the University Bonn and it conforms to the provisions of the Declaration of Helsinki. Ethics approval no.: 347/19. All informed consent was obtained from the subjects. None. None.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRNA, CircularProstateHumansMaleBiopsyMiddle AgedAgedBiomarkers, Tumor

Stichwörter der Autor:innen

ZMIZ1biomarkercircRNAprostate cancerserum

Substanzen

RNA, CircularBiomarkers, Tumor

Autor:innen und Institutionen

  • Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany.
  • Universitätsklinikum Bonn, Institut für Pathologie, Bonn, Germany.

ORCID-Profile: Philipp Krausewitz, Jörg Ellinger

Zitieren

APA

Samirae, L., Krausewitz, P., Alajati, A., Kristiansen, G., Ritter, M., & Ellinger, J. (2024). The relevance of circRNAs in serum of patients undergoing prostate biopsy. International Journal of Urology. https://doi.org/10.1111/iju.15414

Vancouver

Samirae L, Krausewitz P, Alajati A, Kristiansen G, Ritter M, Ellinger J. The relevance of circRNAs in serum of patients undergoing prostate biopsy. International Journal of Urology. 2024. doi:10.1111/iju.15414

BibTeX
@article{Samirae2024,
  author = {Samirae, Lara and Krausewitz, Philipp and Alajati, Abdullah and Kristiansen, Glen and Ritter, Manuel and Ellinger, Jörg},
  title = {The relevance of circRNAs in serum of patients undergoing prostate biopsy},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15414}
}
Kostenlos starten →